{"friendlyName": "Triplegen Stage", "units": [{"evidence": "Julio Moizeszowicz: Society Memberships\nArgentine Medical Association\nArgentine Psychiatric Association\nArgentine College of Psychopharmacology and Neuroscience (board member)\nAmerican Psychiatric Association (International member)\nNew York Academy of Sciences (International member)\n", "description": "Julio Moizeszowicz is related to the following Society: Argentine Medical Association, Argentine, Argentine, American Psychiatric Association, New York Academy of Sciences.", "statements": [["<http://dbpedia.org/resource/Julio%20Moizeszowicz>", "<http://www.w3.org/2004/02/skos/core#related>", "<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>"], ["<http://dbpedia.org/resource/Society>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Society of Julio Moizeszowicz"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<http://dbpedia.org/resource/Argentine_Medical_Association>"], ["<http://dbpedia.org/resource/Argentine_Medical_Association>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Argentine Medical Association"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<http://dbpedia.org/resource/Argentina>"], ["<http://dbpedia.org/resource/Argentina>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Argentine"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<http://dbpedia.org/resource/Argentina>"], ["<http://dbpedia.org/resource/Argentina>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Argentine"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<http://dbpedia.org/resource/American_Psychiatric_Association>"], ["<http://dbpedia.org/resource/American_Psychiatric_Association>", "<http://www.w3.org/2000/01/rdf-schema#label>", "American Psychiatric Association"], ["<https://calvoritmo.com/tfm/entity/e2e4a036-1f4a-4698-bc9d-36c7906ab192>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<http://dbpedia.org/resource/New_York_Academy_of_Sciences>"], ["<http://dbpedia.org/resource/New_York_Academy_of_Sciences>", "<http://www.w3.org/2000/01/rdf-schema#label>", "New York Academy of Sciences"]]}, {"evidence": "Julio Moizeszowicz: Publications\n'Psicofarmacolog\u00eda Psicodin\u00e1mica IV. Estrategias terap\u00e9uticas y psiconeurobiol\u00f3gicas' (Psychodynamic Psychopharmacology IV. Therapeutic and psycho-neurobiological strategies), Editorial Paid\u00f3s, Buenos Aires, 1998.                                                                                                                       (ISBN\u00a0950-12-3180-1).\n'Psicofarmacolog\u00eda y Territorio Freudiano. Teor\u00eda y cl\u00ednica de un abordaje interdisciplinario', (Psychopharmacology and Freudian Territory. A Theory and Clinical interdisciplinary approach), en colaboraci\u00f3n con Mirta Moizeszowicz, Editorial Paid\u00f3s, Buenos Aires, 2000. (ISBN\u00a0950-12-4229-3).\n'Psicof\u00e1rmacos en Geriatr\u00eda', (Psychotropic Drugs in Geriatrics), en colaboraci\u00f3n con Myriam Monczor, Editorial McGraw- Hill Interamericana, Buenos Aires, 2001 y 2012.                                                   (ISBN\u00a0958-41-0272-9).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2009'. (Updates on Psychodynamic Psychopharmacology 2009), Ediciones Roche, Buenos Aires, 2009.                                                                                        (ISBN\u00a0978-987-25235-0-3),\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2008'. (Updates on Psychodynamic Psychopharmacology 2008), Ediciones Roche, Buenos Aires, 2008.                                                                   (ISBN\u00a0978-987-05-4742-6).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2007'. (Updates on Psychodynamic Psychopharmacology 2007), Ediciones Roche, Buenos Aires, 2007.                                                                  (ISBN\u00a0978-987-05-3015-2).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2006'. (Updates on Psychodynamic Psychopharmacology 2006), Ediciones Roche, Buenos Aires, 2006.                                                                   (ISBN\u00a0978-987-05-1263-9).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2005'. (Updates on Psychodynamic Psychopharmacology 2005), Ediciones Roche, Buenos Aires, 2005.                                                                  (ISBN\u00a0987-43-9579-6).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2004'. (Updates on Psychodynamic Psychopharmacology 2004), Ediciones Roche, Buenos Aires, 2004.                                                                    (ISBN\u00a0987-43-8089-6).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2003'. (Updates on Psychodynamic Psychopharmacology 2003), Ediciones Roche, Buenos Aires, 2003.                                                                                (ISBN\u00a0987-43-6307-X).\n'Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2002'. (Updates on Psychodynamic Psychopharmacology 2002), Ediciones Roche, Buenos Aires, 2002.                                                                    (ISBN\u00a0987-43-4914-X).\n'Urgencias Psiqui\u00e1tricas', Cap\u00edtulo en el libro de Emergencias M\u00e9dicas y Quir\u00fargicas ('Psychiatric Emergencies', chapter in the book Medical and Surgical Emergencies, Gerardo Bare y otros), en colaboraci\u00f3n con Roberto Bronstein, Ediciones Edimed, Buenos Aires, 1994. (ISBN\u00a0950-9275-19-0).\n'Psicofarmacolog\u00eda Psicodin\u00e1mica III. Nuevos enfoques cl\u00ednico-terap\u00e9uticos'. (Psychodynamic Psychopharmacology III. New clinical and therapeutical approaches), Editorial Paid\u00f3s, Buenos Aires, 1994.  (ISBN\u00a0950-12-3139-9).\n'Psicofarmacolog\u00eda Psicodin\u00e1mica II. Aspectos neuroqu\u00edmicos, neuropsiqui\u00e1tricos y psicol\u00f3gicos' (Psychodynamic Psychopharmacology II. Neurochemical, neuropsychiatric and psychological aspects), Editorial Paid\u00f3s, Buenos Aires, 1994.                                                                                                                     (ISBN\u00a0950-12-3116-X).\n'Psicofarmacolog\u00eda Psicodin\u00e1mica I. Aspectos neuroqu\u00edmicos y psicol\u00f3gicos'. (Psychodynamic Psychopharmacology I. Neurochemical and psychological aspects), Editorial Paid\u00f3s, Buenos Aires, 1982.                                                                                                                                                 (ISBN\u00a0950-12-3102-X).\nUtilidad de la potenciaci\u00f3n con antipsic\u00f3ticos at\u00edpicos, en la depresi\u00f3n resistente. 26\u00b0 Congreso Argentino de Psiquiatr\u00eda, Asociaci\u00f3n de Psiquiatras Argentinos, Mar del Plata, Hotel Sheraton, 19-22 Abril 2012.\nVi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento. 26\u00b0 Congreso Argentino de Psiquiatr\u00eda, Asociaci\u00f3n de Psiquiatras Argentinos, Mar del Plata, Hotel Sheraton, 21-24 Abril 2010\nPsicofarmacolog\u00eda del espectro \u00bfborder-bipolar? 17\u00b0 Congreso Internacional de Psiquiatr\u00eda, Asociaci\u00f3n Argentina de Psiquiatras, Buenos Aires, Hotel Sheraton, 27-30 septiembre 2010.\nBurn Out. 16\u00b0 Congreso Internacional de Psiquiatr\u00eda, Asociaci\u00f3n Argentina de Psiquiatras, Buenos Aires, Hotel Sheraton Libertador, 3-6 Octubre 2009.\nVi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento. 25\u00b0 Congreso Argentino de Psiquiatr\u00eda, Asociaci\u00f3n de Psiquiatras Argentinos, Mar del Plata, Hotel Sheraton, 22-25 Abril 2009.\nImpulsividad/Vulnerabilidad. \u00bfTratamiento psicofarmacol\u00f3gico y/o Resiliencia. Simposio Pipelines Drugs, Buenos Aires, Hotel Caesar Park, 4 Noviembre 2008.\nQu\u00e9 significa ser At\u00edpico en el tratamiento de las psicosis. Riesgos y Beneficios. Utilidad de un nuevo Antipsic\u00f3tico At\u00edpico. 23\u00b0 Congreso Argentino de Psiquiatr\u00eda, Asociaci\u00f3n de Psiquiatras Argentinos, Mar del Plata, Hotel Sheraton, 19-22 Abril 2007.\nTratamiento de la Depresi\u00f3n en el largo plazo. Simposio Neurociencias, Buenos Aires, Hotel Piazzola, 29 Agosto 2005\nControversial question: Should psychomotor retardation be considered as a good prognostic factor in the treatment of depression?, Medicographia 2003; 25 (74): 47.\nEscitalopram in the treatment of mayor depression disorder with anxiety in a routine clinical outpatient clinic. Fern\u00e1ndez L., Bronstein R., Schaumann C., Pedemonte P. Moizeszowicz J., 24th. CINP Congress, Collegium Internationale Neuro-Psychofarmacologicum, Par\u00eds, Francia, 20-24 junio 2004.\nAt\u00edpicos, antipsic\u00f3ticos de vanguardia. Diario La Naci\u00f3n, 17-18 abril de 2004.\nGrowth Hormone Neurosecretory Disfunction in Major Depressive Illness. Fiasche R., Fideleff H., Moizeszowicz J., Frieder P., Pagano SM., Holland M., Psychoneuroendocrinology 1995; 20: 727-733.\n'Tratamiento Psicofarmacol\u00f3gico en Cl\u00ednica de D\u00eda'. En Moizeszowicz J., Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos. Editorial Paid\u00f3s, Buenos Aires, 1994, Cap\u00edtulo 14, p\u00e1gs. 715\u2013730. (ISBN\u00a0978-950-12-3139-7).\n'Tratamiento Psicofarmacol\u00f3gico de la Bulimia Nerviosa'. En Moizeszowicz J., Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos. Editorial Paid\u00f3s, Buenos Aires, 1994, Cap\u00edtulo 12, p\u00e1gs. 681\u2013691. (ISBN\u00a0978-950-12-3139-7).\nPsicof\u00e1rmacos y Terapia por la Palabra, en un Sobrio Debate. Diario Tiempo Argentino, 30 marzo 1983.\nComo Combatir la Depresi\u00f3n, Diario Clar\u00edn, 2 diciembre 1983.\nEffects of a New Benzodiazepine Derivative in Anxious Patients with gastrointestinal Disorders. Laudano O., Peralta M., Luj\u00e1n L., Aparicio N., Moizeszowicz J., Journal of Clinical Pharmacology 1977; 17: 441\u2013446.\nControlled Trial of Nomifensin and Viloxazine in the Treatment of Depression in the Elderly. Moizeszowicz J., Subir\u00e1 S., Journal of Clinical Pharmacology 1977; 17: 81\u201383.\nUtilidad de la Diferenciaci\u00f3n de Benzodiacepinas en el Tratamiento de la Ansiedad. Chappa H., Moizeszowicz J., Prensa M\u00e9dica Argentina 1976; 63: 339\u2013342.\nTratamiento de las Neurosis Depresivas-Ansiosas con un Nuevo Psicof\u00e1rmaco: Nomifensin. Chappa H., Levin E., Moizeszowicz J., Acta Psiqui\u00e1trica y Psicolog\u00eda de Am\u00e9rica Latina 1976; 22: 133\u2013138.\nEvaluaci\u00f3n del Insomnio por Escalas de Autoadministraci\u00f3n. Effectividad de un Nuevo Hipn\u00f3tico Benzodiacep\u00ednico Soluble. Moizeszowicz J., C\u00faneo G., Guitelman A., Semana M\u00e9dica 1976; 149: 116\u2013120.\nA Double Blind Comparative Trial of Nomifensin and Desipramine in Depression. Relation Between Treatment and Phenylethylamine Excretion. Acebal E., Subir\u00e1 S.,  Spatz H., Faleni R., Merzbacher B., Gales A., Moizeszowicz J., European Journal of Clinical Pharmacology 1976; 10: 109\u2013113.\nEvaluation of the Psychotropic Effect of Etifoxina through Pursuit Rotor Performance and Galvanic Skin Response. C\u00f3rsico R., Moizeszowicz J., Bursuk L.,  Rovaro E., Psychopharmacology (Berl) 1976; 45: 301\u2013303.\nActualizaci\u00f3n en la Evaluaci\u00f3n Cl\u00ednica de Psicof\u00e1rmacos. Acta Psiqui\u00e1trica y Psicol\u00f3gica de Am\u00e9rica Latina 1975; 21: 41\u201351.\nNeurocognitive Components of Chronic Schizophrenia. Fiszbein, A., Opler, L.A., Kay S. R., Rosenkilde, C.E., Ramirez, P. M., Moizeszowicz, J., and Gorelick, A. S.  Program and Papers on New Research Syllabus, The One Hundred and Forty-Fourth Meeting of the American Psychiatric Association, New Orleans, USA, 1991; NR3.\n", "description": "Julio Moizeszowicz is related to the following Publications: Psicofarmacolog\u00eda Psicodin\u00e1mica IV. Estrategias terap\u00e9uticas y psiconeurobiol\u00f3gicas, Psicofarmacolog\u00eda y Territorio Freudiano. Teor\u00eda y cl\u00ednica de un abordaje interdisciplinario, Psicof\u00e1rmacos en Geriatr\u00eda, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2009, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2008, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2007, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2006, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2005, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2004, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2003, Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2002, Emergencias M\u00e9dicas y Quir\u00fargicas, Psicofarmacolog\u00eda Psicodin\u00e1mica III. Nuevos enfoques cl\u00ednico-terap\u00e9uticos, Psicofarmacolog\u00eda Psicodin\u00e1mica II. Aspectos neuroqu\u00edmicos, neuropsiqui\u00e1tricos y psicol\u00f3gicos, Psicofarmacolog\u00eda Psicodin\u00e1mica I. Aspectos neuroqu\u00edmicos y psicol\u00f3gicos, Utilidad de la potenciaci\u00f3n con antipsic\u00f3ticos at\u00edpicos, en la depresi\u00f3n resistente, Vi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento, Psicofarmacolog\u00eda del espectro \u00bfborder-bipolar?, Burn Out. 16\u00b0 Congreso Internacional de Psiquiatr\u00eda, Asociaci\u00f3n Argentina de Psiquiatras, Vi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento, Impulsividad/Vulnerabilidad. \u00bfTratamiento psicofarmacol\u00f3gico y/o Resiliencia, Qu\u00e9 significa ser At\u00edpico en el tratamiento de las psicosis. Riesgos y Beneficios. Utilidad de un nuevo Antipsic\u00f3tico At\u00edpico, Tratamiento de la Depresi\u00f3n en el largo plazo, Controversial question: Should psychomotor retardation be considered as a good prognostic factor in the treatment of depression?, Escitalopram in the treatment of mayor depression disorder with anxiety in a routine clinical outpatient clinic, At\u00edpicos, antipsic\u00f3ticos de vanguardia, Growth Hormone Neurosecretory Disfunction in Major Depressive Illness, Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos, Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos, Psicof\u00e1rmacos y Terapia por la Palabra, en un Sobrio Debate, Como Combatir la Depresi\u00f3n, Effects of a New Benzodiazepine Derivative in Anxious Patients with gastrointestinal Disorders, Controlled Trial of Nomifensin and Viloxazine in the Treatment of Depression in the Elderly, Utilidad de la Diferenciaci\u00f3n de Benzodiacepinas en el Tratamiento de la Ansiedad, Tratamiento de las Neurosis Depresivas-Ansiosas con un Nuevo Psicof\u00e1rmaco: Nomifensin, Evaluaci\u00f3n del Insomnio por Escalas de Autoadministraci\u00f3n. Effectividad de un Nuevo Hipn\u00f3tico Benzodiacep\u00ednico Soluble, A Double Blind Comparative Trial of Nomifensin and Desipramine in Depression. Relation Between Treatment and Phenylethylamine Excretion, Evaluation of the Psychotropic Effect of Etifoxina through Pursuit Rotor Performance and Galvanic Skin Response, Actualizaci\u00f3n en la Evaluaci\u00f3n Cl\u00ednica de Psicof\u00e1rmacos, Neurocognitive Components of Chronic Schizophrenia.", "statements": [["<http://dbpedia.org/resource/Julio%20Moizeszowicz>", "<http://www.w3.org/2004/02/skos/core#related>", "<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>"], ["<http://dbpedia.org/resource/Publications>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Publications of Julio Moizeszowicz"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/b853b399-32a2-4ea1-9c38-6eb09ae6376d>"], ["<https://calvoritmo.com/tfm/entity/b853b399-32a2-4ea1-9c38-6eb09ae6376d>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica IV. Estrategias terap\u00e9uticas y psiconeurobiol\u00f3gicas"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/cbbf45bd-fed9-4a04-959b-81221131da3b>"], ["<https://calvoritmo.com/tfm/entity/cbbf45bd-fed9-4a04-959b-81221131da3b>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda y Territorio Freudiano. Teor\u00eda y cl\u00ednica de un abordaje interdisciplinario"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/54645abb-ad24-4a73-807a-635845659421>"], ["<https://calvoritmo.com/tfm/entity/54645abb-ad24-4a73-807a-635845659421>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicof\u00e1rmacos en Geriatr\u00eda"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/ebf32075-3224-4952-ab60-a34970c0784b>"], ["<https://calvoritmo.com/tfm/entity/ebf32075-3224-4952-ab60-a34970c0784b>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2009"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/92db0148-afc0-4a54-88dc-639672040fff>"], ["<https://calvoritmo.com/tfm/entity/92db0148-afc0-4a54-88dc-639672040fff>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2008"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/48aef508-6345-4694-8558-3663ce9c1e7e>"], ["<https://calvoritmo.com/tfm/entity/48aef508-6345-4694-8558-3663ce9c1e7e>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2007"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/15fb23ad-f810-4bb4-b86c-c8b3ca78265e>"], ["<https://calvoritmo.com/tfm/entity/15fb23ad-f810-4bb4-b86c-c8b3ca78265e>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2006"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/d16891c3-9141-49b2-83ef-e89352c06596>"], ["<https://calvoritmo.com/tfm/entity/d16891c3-9141-49b2-83ef-e89352c06596>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2005"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/55ba4f44-5428-4a2f-a0c2-8cef699f17d1>"], ["<https://calvoritmo.com/tfm/entity/55ba4f44-5428-4a2f-a0c2-8cef699f17d1>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2004"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/7ec67ef7-5015-430f-ba57-27f592a6b4fe>"], ["<https://calvoritmo.com/tfm/entity/7ec67ef7-5015-430f-ba57-27f592a6b4fe>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2003"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/e8c8ba1a-2def-46be-893c-8e56fe186227>"], ["<https://calvoritmo.com/tfm/entity/e8c8ba1a-2def-46be-893c-8e56fe186227>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaciones en Psicofarmacolog\u00eda Psicodin\u00e1mica 2002"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/7d7afd7f-29c4-4008-a14d-dc3f78523638>"], ["<https://calvoritmo.com/tfm/entity/7d7afd7f-29c4-4008-a14d-dc3f78523638>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Emergencias M\u00e9dicas y Quir\u00fargicas"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/f6e5d080-1dda-4ee1-9845-534b14024d93>"], ["<https://calvoritmo.com/tfm/entity/f6e5d080-1dda-4ee1-9845-534b14024d93>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica III. Nuevos enfoques cl\u00ednico-terap\u00e9uticos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/23cdf284-a643-41b0-9e99-c963750eb2c9>"], ["<https://calvoritmo.com/tfm/entity/23cdf284-a643-41b0-9e99-c963750eb2c9>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica II. Aspectos neuroqu\u00edmicos, neuropsiqui\u00e1tricos y psicol\u00f3gicos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/551e4306-0c33-4944-900d-4e9e67aeac46>"], ["<https://calvoritmo.com/tfm/entity/551e4306-0c33-4944-900d-4e9e67aeac46>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica I. Aspectos neuroqu\u00edmicos y psicol\u00f3gicos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/cfa104ae-c019-471a-97e4-423489fe6dfa>"], ["<https://calvoritmo.com/tfm/entity/cfa104ae-c019-471a-97e4-423489fe6dfa>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Utilidad de la potenciaci\u00f3n con antipsic\u00f3ticos at\u00edpicos, en la depresi\u00f3n resistente"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/72e5e7a3-1c45-4766-937e-c7cb0e77f502>"], ["<https://calvoritmo.com/tfm/entity/72e5e7a3-1c45-4766-937e-c7cb0e77f502>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Vi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/9fc23210-a4ee-4591-95c5-01ec00ccbd44>"], ["<https://calvoritmo.com/tfm/entity/9fc23210-a4ee-4591-95c5-01ec00ccbd44>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda del espectro \u00bfborder-bipolar?"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/13cde7d7-f4eb-44c2-b635-a69c8f3a3fd9>"], ["<https://calvoritmo.com/tfm/entity/13cde7d7-f4eb-44c2-b635-a69c8f3a3fd9>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Burn Out. 16\u00b0 Congreso Internacional de Psiquiatr\u00eda, Asociaci\u00f3n Argentina de Psiquiatras"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/9e97294a-2c10-4616-8a91-f04c3c2e9bf5>"], ["<https://calvoritmo.com/tfm/entity/9e97294a-2c10-4616-8a91-f04c3c2e9bf5>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Vi\u00f1etas Cl\u00ednicas Interactivas: Actualidad diagn\u00f3stica y de tratamiento"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/3ffb8658-78e7-4ce6-a1ca-9880f2baa29b>"], ["<https://calvoritmo.com/tfm/entity/3ffb8658-78e7-4ce6-a1ca-9880f2baa29b>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Impulsividad/Vulnerabilidad. \u00bfTratamiento psicofarmacol\u00f3gico y/o Resiliencia"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/9155d936-e67f-41fd-a26f-c55f487ae409>"], ["<https://calvoritmo.com/tfm/entity/9155d936-e67f-41fd-a26f-c55f487ae409>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Qu\u00e9 significa ser At\u00edpico en el tratamiento de las psicosis. Riesgos y Beneficios. Utilidad de un nuevo Antipsic\u00f3tico At\u00edpico"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/6fcc3de8-a0e1-4332-8f94-b165faf357b1>"], ["<https://calvoritmo.com/tfm/entity/6fcc3de8-a0e1-4332-8f94-b165faf357b1>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Tratamiento de la Depresi\u00f3n en el largo plazo"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/de2a3da6-b2c4-4b07-a729-fc1cb12c160b>"], ["<https://calvoritmo.com/tfm/entity/de2a3da6-b2c4-4b07-a729-fc1cb12c160b>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Controversial question: Should psychomotor retardation be considered as a good prognostic factor in the treatment of depression?"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/53a3755c-a3d0-4130-8be9-0fa49b6ca04a>"], ["<https://calvoritmo.com/tfm/entity/53a3755c-a3d0-4130-8be9-0fa49b6ca04a>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Escitalopram in the treatment of mayor depression disorder with anxiety in a routine clinical outpatient clinic"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/34e76e34-a1ed-4211-abd6-9f38d42b7a09>"], ["<https://calvoritmo.com/tfm/entity/34e76e34-a1ed-4211-abd6-9f38d42b7a09>", "<http://www.w3.org/2000/01/rdf-schema#label>", "At\u00edpicos, antipsic\u00f3ticos de vanguardia"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/24c33242-a21d-4103-968f-28e55ade8c38>"], ["<https://calvoritmo.com/tfm/entity/24c33242-a21d-4103-968f-28e55ade8c38>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Growth Hormone Neurosecretory Disfunction in Major Depressive Illness"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/72c4d82b-eeb8-4d1c-b58e-be40914e2948>"], ["<https://calvoritmo.com/tfm/entity/72c4d82b-eeb8-4d1c-b58e-be40914e2948>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/80316166-66a2-4455-8c85-aea1207bf28f>"], ["<https://calvoritmo.com/tfm/entity/80316166-66a2-4455-8c85-aea1207bf28f>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicofarmacolog\u00eda Psicodin\u00e1mica III: Nuevos enfoques cl\u00ednico-terap\u00e9uticos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/d9b9b614-63d0-4568-8e09-da92fa35a469>"], ["<https://calvoritmo.com/tfm/entity/d9b9b614-63d0-4568-8e09-da92fa35a469>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Psicof\u00e1rmacos y Terapia por la Palabra, en un Sobrio Debate"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/40a82db8-ffa8-4574-93a0-a58c9529ca6a>"], ["<https://calvoritmo.com/tfm/entity/40a82db8-ffa8-4574-93a0-a58c9529ca6a>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Como Combatir la Depresi\u00f3n"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/64ebb06a-1f6d-440a-836d-7ca3b8537c5f>"], ["<https://calvoritmo.com/tfm/entity/64ebb06a-1f6d-440a-836d-7ca3b8537c5f>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Effects of a New Benzodiazepine Derivative in Anxious Patients with gastrointestinal Disorders"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/39f17330-bd1c-44bb-97e6-5050d3ae33a4>"], ["<https://calvoritmo.com/tfm/entity/39f17330-bd1c-44bb-97e6-5050d3ae33a4>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Controlled Trial of Nomifensin and Viloxazine in the Treatment of Depression in the Elderly"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/9cf0266d-4ed6-4707-af6d-48eae36d6e6d>"], ["<https://calvoritmo.com/tfm/entity/9cf0266d-4ed6-4707-af6d-48eae36d6e6d>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Utilidad de la Diferenciaci\u00f3n de Benzodiacepinas en el Tratamiento de la Ansiedad"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/27d6fdb3-e0f4-4c67-8caa-317164a06ec9>"], ["<https://calvoritmo.com/tfm/entity/27d6fdb3-e0f4-4c67-8caa-317164a06ec9>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Tratamiento de las Neurosis Depresivas-Ansiosas con un Nuevo Psicof\u00e1rmaco: Nomifensin"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/fa300e8d-55f0-4c32-a409-42a45c9b809c>"], ["<https://calvoritmo.com/tfm/entity/fa300e8d-55f0-4c32-a409-42a45c9b809c>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Evaluaci\u00f3n del Insomnio por Escalas de Autoadministraci\u00f3n. Effectividad de un Nuevo Hipn\u00f3tico Benzodiacep\u00ednico Soluble"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/8decf1ac-cc2a-41c8-aa08-66f857fcb718>"], ["<https://calvoritmo.com/tfm/entity/8decf1ac-cc2a-41c8-aa08-66f857fcb718>", "<http://www.w3.org/2000/01/rdf-schema#label>", "A Double Blind Comparative Trial of Nomifensin and Desipramine in Depression. Relation Between Treatment and Phenylethylamine Excretion"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/617f6c4f-f2a2-4d03-9323-997554d47d36>"], ["<https://calvoritmo.com/tfm/entity/617f6c4f-f2a2-4d03-9323-997554d47d36>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Evaluation of the Psychotropic Effect of Etifoxina through Pursuit Rotor Performance and Galvanic Skin Response"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/4686fb4a-56ee-48ac-95fe-2abd7a815c71>"], ["<https://calvoritmo.com/tfm/entity/4686fb4a-56ee-48ac-95fe-2abd7a815c71>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Actualizaci\u00f3n en la Evaluaci\u00f3n Cl\u00ednica de Psicof\u00e1rmacos"], ["<https://calvoritmo.com/tfm/entity/55f31c86-d8a7-466a-9524-d1bca23f4684>", "<http://www.w3.org/2004/02/skos/core#narrower>", "<https://calvoritmo.com/tfm/entity/1c858835-28a3-42fc-9dd3-fb08e1059429>"], ["<https://calvoritmo.com/tfm/entity/1c858835-28a3-42fc-9dd3-fb08e1059429>", "<http://www.w3.org/2000/01/rdf-schema#label>", "Neurocognitive Components of Chronic Schizophrenia"]]}]}